Abstract grid and lines

Blog articles

Driving diversity in UK venture capital

8 March 2022: Ahead of International Women’s Day on 8 March, Judith Hartley, CEO of British Patient Capital, comments on the need for more diversity within the UK venture capital industry:

International Women’s Day shines a light on the amazing work of women across multiple industries. However, it also serves as an important reminder that a lack of diversity remains an ongoing issue, especially within the venture capital industry.

Currently, only 13.3% of VC firms and business angel groups have women in investment decision-making roles, despite growing evidence that diverse teams are more innovative and generate higher revenues. The findings of last week’s Rose Review Progress Report are encouraging but remind us that funding remains the number one barrier facing female entrepreneurs at every stage of their business journey. Total VC investment levels in female founders remain at under 5%, according to British Business Bank analysis of Beauhurst data.

There is huge latent economic potential to be uncovered by increasing investment in female entrepreneurs. When first published in 2019, the Alison Rose Review of Female Entrepreneurship estimated that up to £250bn of new value could be added to the UK economy if women started and scaled new businesses at the same rate as men. Furthermore, Morgan Stanley has estimated that venture capital funds that fail to invest in women and other under-represented groups risk losing out on as much as $4.4tn.

British Patient Capital is the largest domestic investor in UK venture and venture growth capital and we want to help improve diversity within our sector. Within our own business, we work hard to ensure we have a good diversity at all levels: three out of four of our Board members are female and our wider team includes individuals from a diverse range of backgrounds. We have also adopted the Institutional Limited Partners Association (ILPA) diversity template as part of our standard due diligence process, which enables us to assess investment opportunities on their diversity characteristics and capture data on a range of diversity-related areas, including gender and ethnicity, with a view to driving greater diversity within our investments.

Within our portfolio of fund managers, we work with some incredible women who are in leading positions in their fields. These include Kate Bingham, Managing Partner at SV Health Investors and chair of the UK Government’s COVID-19 Vaccine Taskforce in 2020; Irina Haivas, Partner at Atomico, who led their investment in Healx, a company that uses AI to find cures for rare diseases; and Kerry Baldwin, Managing Partner of IQ Capital and BVCA Chair for 2021/22. We engage with our fund managers, to help them improve their approach to diversity and inclusion within their own teams and also in the companies they back. As the leading investor in UK venture and venture growth, we firmly believe we have a role to play in demonstrating best practice and driving change in this area.

We welcome the extra measures proposed by the Rose Review Board to boost support for female entrepreneurs and help close the gender gap within the investment community, including the Investing in Women Code and the Women Backing Women campaign. These initiatives are incredibly important, yet more can still be done. We all have a role to play in closing the gender and diversity gap in VC, not only because it is a social good in itself but also because it is good for business, leading to better performance and better returns.

ENDS

About British Patient Capital

British Patient Capital is the trading name of British Patient Capital Limited, a wholly-owned commercial subsidiary of British Business Bank plc, the UK government’s economic development bank. It forms part of the British Business Bank’s plc’s commercial arm.

Its mission is to enable long-term investment in innovative firms led by ambitious entrepreneurs who want to build large scale businesses. Launched in June 2018, British Patient Capital has £2.5bn to invest over 10 years in venture and venture growth capital to support high growth potential innovative UK businesses in accessing the long-term financing they require to scale up. Find out more at britishpatientcapital.co.uk.

British Business Bank plc and its subsidiary entities are not banking institutions and do not operate as such. They are not authorised or regulated by the Prudential Regulation Authority (PRA) or the Financial Conduct Authority (FCA). A complete legal structure chart for British Business Bank plc and its subsidiaries can be found on the British Business Bank plc website.

British Patient Capital makes commitments and invests on its own behalf and on behalf of third-party investors whose investments British Patient Capital manages.

For more information

Tom Allchorne

Senior Communications Manager
Phone: 07785 651899 or 020 3908 0334
Email: thomas.allchorne@bpcinv.co.uk

Lansons

British Patient Capital team at Lansons
Phone: 020 7294 3636
Email: BritishPatientCapital@lansons.com